CAJ | 학술논문

目的探讨恶性肿瘤并发慢性乙型病毒性肝炎患者应用替比夫定治疗的临床疗效.方法纳入42例恶性肿瘤并发慢性乙型病毒性肝炎患者,根据是否应用替比夫定进行抗病毒治疗分为试验组及对照组,试验组患者在进行放化疗前1w开始应用替比夫定进行抗病毒治疗,对照组患者仅进行放化疗治疗,不行抗病毒治疗.两组患者中的部分患者辅以护肝治疗,但均未使用降酶药物.结果治疗后发现试验组患者HBV DNA的下降以及血清ALT(AST)的改善率均优于对照组患者,两组间差异有统计学意义(P＜0.01).结论对恶性肿瘤合并慢性乙型病毒性肝炎患者使用替比夫定抗病毒治疗能够有效的预防放化疗后所引起的乙肝病毒激活.
목적 탐토악성종류병발만성을형병독성간염환자응용체비부정치료적림상료효.방법 납입42례악성종류병발만성을형병독성간염환자,근거시부응용체비부정진행항병독치료분위시험조급대조조,시험조환자재진행방화료전1w개시응용체비부정진행항병독치료,대조조환자부진행방화료치료,불행항병독치료.량조환자중적부분환자보이호간치료,단균미사용강매약물.결과 치료후발현시험조환자HBV DNA적하강이급혈청ALT(AST)적개선솔균우우대조조환자,량조간차이유통계학의의(P＜0.01).결론 대악성종류합병만성을형병독성간염환자사용체비부정항병독치료능구유효적예방방화료후소인기적을간병독격활.
Objective To investigate the clinical effect of telbivudine treatment application in malignant tumor patients with chronic hepatitis B.Methods A total of 42 cases of malignant tumor complicated with chronic hepatitis B patients were included in the study.The objects were divided into experimental group and control group according to whether using telbivudine antiviral treatment.The patients in experimental group began to use telbivudine antiviral chemotherapy treatment a week before radiotherapy and chemotherapy.The patients in the control group only accepted radiotherapy.Some patients in these two groups accepted guard liver therapy, but the drop enzyme drug was not used.Results HBV DNA decreased and serum ALT (AST) improvement rate were better than the patients in the control group after treatment.There was statistical significant difference between the two groups (P ＜ 0.01).Conclusions The treatment can cause effective preventive chemotherapy after use telbivudine antiviral hepatitis B virus activation in chronic hepatitis B patients of malignant tumor.